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Abstract  
Early-onset conduct problems (CP) are a key predictor of adult criminality and poor mental 
health. While previous studies suggest that both genetic and environmental risks play an 
important role in the development of early-onset CP, little is known about potential biological 
processes underlying these associations. In this study, we examined prospective associations 
between DNA methylation (cord blood at birth) and trajectories of CP (4-13yrs), using data 
drawn from the Avon Longitudinal Study of Parents and Children (ALSPAC). Methylomic 
variation at seven loci across the genome (FDR<0.05) differentiated children who go on to 
develop early-onset (n = 174) vs low (n = 86) CP, including sites in the vicinity of MGLL 
(involved in endocannabinoid signaling and pain perception). Sub-threshold associations in 
the vicinity of three candidate genes for CP (MAOA, BDNF, and FKBP5) were also 
identified. Within the early-onset CP group, methylation levels of the identified sites did not 
distinguish children who will go on to persist vs desist in CP behavior over time. Overall, we 
found that several of the identified sites correlated with prenatal exposures, and none were 
linked to known genetic mQTLs. Findings contribute to a better understanding of epigenetic 
patterns associated with early-onset CP. 
Keywords: DNA Methylation; genome-wide; ALSPAC; conduct problems; risk exposure 
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Introduction 
Conduct problems (CP; e.g. fighting, stealing) are a major public health concern and a 
leading cause of youth treatment referral (Bywater, 2012). CP youth engage in antisocial and 
disruptive behaviors that result in significant distress to victims, impairment of life 
opportunities and economic burden on judicial, healthcare and social welfare services 
(Colman et al., 2009). In particular, an early-onset of CP (at or before the age of 10) 
designates a high-risk group of children, who show more severe and recidivistic patterns of 
antisocial behavior, higher levels of comorbid psychopathology (E. D. Barker, Oliver, & 
Maughan, 2010), increased risk for poor adult outcomes (Fergusson, John Horwood, & 
Ridder, 2005; Odgers et al., 2007), and who account for the majority of criminal offences 
within a given community (David P. Farrington, 2001). Consequently, early-onset CP are 
recognized as an important target for prevention and intervention efforts.  
Like most complex phenotypes, early-onset CP are thought to result from the 
developmentally dynamic interplay of genetic and environmental influences. Studies have 
shown that the heritability of early-onset CP is moderate to high (~50-80%, see Barker, Cecil, 
Walton & Meehan, in press, for a review) and that this genetic vulnerability interacts with 
environmental risk exposure (e.g. Jaffee et al., 2005). Indeed, exposure to adversity during 
pregnancy (e.g. maternal smoking, stress and psychopathology) as well as the postnatal years 
(e.g. maltreatment, poverty) is frequent among this group of children, and thought to play an 
important role in the development and persistence of CP behavior (E. D. Barker & Maughan, 
2009; T. E. Moffitt, 2006; Odgers et al., 2007; Odgers et al., 2008). Yet, little is known about 
the biological mechanisms through which these influences confer increased risk for early-
onset CP. 
In recent years, DNA methylation – an epigenetic mechanism that regulates gene 
expression (Jaenisch & Bird, 2003) – has emerged as a potential mechanism underlying gene-
environment interplay and disease susceptibility across the lifespan. Specifically, studies have 
shown that (i) DNAm patterns are under significant genetic control – as evidenced by the 
discovery of a large number of methylation quantitative trait loci (mQTL; Gaunt et al., 2016; 
Jones, Fejes, & Kobor, 2013); and (ii) DNAm is also sensitive to environmental influences 
(McGowan & Roth, 2015), including numerous nutritional, chemical, physical, and 
psychosocial exposures occurring in utero (e.g. Monk, Spicer, & Champagne, 2012; 
Richmond et al., 2015; Tobi et al., 2014) and postnatally (Lutz & Turecki, 2014; Szyf & 
Bick, 2013; Tyrka et al., 2015). In turn, DNAm patterns have been shown to play a central 
role in neurobiological and developmental processes (e.g. neurogenesis, synaptic plasticity, 
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learning and memory; Murgatroyd & Spengler, 2011) and aberrations in DNAm have been 
implicated in a range of negative outcomes, including childhood psychopathology and stress-
related psychiatric disorders (Klengel, Pape, Binder, & Mehta, 2014; van Mil et al., 2014; 
Weder et al., 2014).  Consequently, it has been suggested that DNAm may represent a 
molecular pathway through which environmental exposures become translated into 
phenotypic variation, conferring increased susceptibility to mental and physical health 
problems (Kofink, Boks, Timmers, & Kas, 2013; Lewis & Olive, 2014).  
For example, experimental studies in animals have shown that exposure to early 
adversity (e.g. prenatal stress, low postnatal care) can cause alterations in offspring DNAm 
(e.g. in HPA-axis genes), driving differences in the offspring’s behavioral response to future 
stressors (Weaver et al., 2004; Turecki & Meaney, 2016). Indeed, because DNAm marks can 
be passed on during cell division (and in some cases across generations), they can lead to 
long-term programming of gene expression, with downstream effects on stress sensitivity, 
behavior and disease risk (Rodgers & Bale, 2011; Zannas & West, 2014). In the context of 
CP, epigenetic alterations may thus represent a mechanism through which genetic and 
environmental factors intersect, influencing developmental trajectories of childhood 
aggression and antisocial behavior (Tremblay & Szyf, 2010). 
So far, only a handful of studies in humans have examined associations between 
DNAm and CP-related phenotypes. Of these, the majority have been carried out by a research 
group comparing patterns of DNAm (extracted from peripheral blood samples collected at 
age 26-28) between adult males with a childhood history of chronic physical aggression (ages 
6-15) vs controls who maintained low levels of physical aggression during the same time 
period, based on data from a longitudinal cohort (Booij et al., 2010; Guillemin et al., 2014; 
Provençal et al., 2013; Provençal et al., 2014; Wang et al., 2012). Using this case-control 
design, these studies reported that childhood aggression associated with (i) higher levels of 
SLC6A4 promoter methylation and lower in vivo levels of brain serotonin synthesis (Booij et 
al., 2010; Wang et al., 2012); (ii) DNAm levels in a set of genes involved in cytokine 
function and inflammation (Provençal et al., 2013); and (iii) across a large number of gene 
promoter regions in an epigenome-wide scan (Provençal et al., 2014) – a finding that was 
later extended to a small sample of adult females as well (Guillemin et al., 2014).  Another 
set of studies based on a sample of antisocial boys diagnosed with oppositional defiant 
disorder or conduct disorder (4-16yrs) have also documented an association between severity 
of callous-unemotional traits (CU; e.g. low capacity for empathy, lack of guilt, shallow 
affect) and DNAm levels (obtained from peripheral blood) across several candidate genes, 
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including lower DNAm of the Serotonin 1B Receptor gene (HTR1B; Moul, Dobson-Stone, 
Brennan, Hawes, & Dadds, 2015), and higher DNAm of the Oxytocin Receptor gene (OXTR; 
Dadds et al., 2014) – which in turn related to lower circulating oxytocin levels. 
Despite these promising findings, research to date has been limited in a number of 
important ways. First, no study to our knowledge has specifically investigated DNAm 
patterns associated with early-onset CP, which designates a subgroup of children at high risk 
for negative adult outcomes. Second, the available research has been primarily cross-
sectional or retrospective with regards to DNAm (i.e. associating behavioral phenotypes in 
childhood to DNAm later in development). As such, it is currently unclear whether observed 
alterations in DNAm patterns represent a risk factor for and/or a consequence of conduct 
problems. In other words, it has not been possible to establish whether DNAm is a 
prospective risk for CP, or alternatively, the biological correlate of a chronic antisocial 
lifestyle. Third, there is a lack of studies integrating measures of the environment, which has 
precluded the possibility of assessing the epigenome in relation to both risk exposure and 
psychiatric phenotypes.   
To address the above gaps, research from our group has begun to assess prospective 
associations between environmental risks, DNAm at repeated time points (birth, childhood) 
and CP-related outcomes, using data from the Avon Longitudinal Study of Parents and 
Children (ALSPAC; Fraser et al., 2013). For example, in children with early-onset CP and 
low internalizing problems, we found that DNAm levels in the promoter region OXTR at 
birth (but not at later points in childhood) associated with higher risk exposure in utero, 
reduced experience of victimization during childhood (i.e. indicative of an ‘evocative 
epigenetic-environment correlation’) and more severe CU traits at age 13 (Cecil et al., 2014). 
Also in early-onset CP, we found that a sugar- and fat-rich diet during pregnancy 
prospectively associated with higher DNAm of the Intrauterine Growth Factor Gene 2 (IGF2) 
at birth (but not during childhood), which, in turn, associated with more severe co-occurring 
ADHD symptoms (Rijslasdaam et al., 2016a). The temporal specificity around birth observed 
across these and other studies (e.g. Cecil et al., 2016; Walton et al., 2016) may reflect a 
number of factors, including large-scale variability in DNAm patterns across developmental 
eras (Gaunt et al., 2016), differences between the tissues examined at each time point (i.e. 
cord blood at birth vs whole blood in childhood), as well as the influence of developmentally-
specific genetic effects on symptom trajectories (e.g. Pingault, Rijsdijk, Zheng, Plomin & 
Viding, 2015). Additionally, findings may lend support for the developmental origins of 
health and disease hypothesis (DOHaD; D. J. Barker, 2007; Nigg, 2016), whereby 
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methylation changes at birth may represent a more reliable proxy for intra-uterine risk 
exposures (compared to DNAm in childhood), and associated perturbations in fetal 
development. However, the extent to which DNAm patterns across the genome at birth may 
prospectively associate with an early-onset of CP has yet to be examined.   
In addition to advancing knowledge of potential biological differences between 
children with early-onset vs low CP, the study of DNAm may also help us to better 
understand why early-onset children themselves show considerable heterogeneity in their 
developmental trajectories of CP. Indeed, studies have found that – despite being considered 
a high-risk group as a whole - less than 50% of children with an early-onset of CP will 
actually continue to exhibit these problems into adolescence (i.e. early-onset persisting 
trajectory, EOP), while the rest will remit to near-typical levels of CP (i.e. childhood-limited 
trajectory, CL; E. D. Barker & Maughan, 2009; Odgers et al., 2008). This heterogeneity 
poses a challenge for accurate diagnostic screening, clinical classification and treatment 
formulation, as well as raising important questions about what factors may underlie these 
increasingly divergent trajectories of CP within early-onset children (i.e. in line with the 
concept of multifinality; Cicchetti & Rogosch, 1996). So far, evidence regarding early-life 
predictors of EOP vs CL trajectories has been somewhat mixed (see Moffitt et al., 2008, for a 
review), but generally suggests that the difference may be more quantitative than qualitative, 
with pre- and postnatal risk exposures found to be particularly high for EOP children, 
compared to their CL peers (i.e. EOP>CL>Low CP; E. D. Barker & Maughan, 2009). 
However, it is currently unknown whether such a ‘graded’ difference on the same risk factors 
may also exist at a biological level. The analysis of DNAm patterns between early-onsets 
who follow different developmental trajectories of CP (i.e. EOP vs CL), may therefore help 
to refine the phenotype and contribute to a better understanding of heterogeneity within this 
high-risk group of children.  
 
The present study 
In light of the above research gaps, we made use of data from the ALSPAC cohort 
spanning pregnancy to late childhood to address three key aims. First, we examined whether 
DNAm patterns at birth (measured at >450,000 sites across the genome) prospectively 
differentiate children who will go on to develop early-onset (n = 174) vs low CP (n = 86). 
Second, to explore heterogeneity in CP trajectories within the early-onset group, we tested 
whether these DNAm patterns further distinguish between children who will persist (EOP; n 
= 91) vs desist (CL; n = 83) in conduct problems over time. Third, we investigated potential 
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genetic and environmental influences associated with the identified DNAm sites, including 
known genetic mQTLs and measures of prenatal adversity that have been previously linked 
to early-onset CP (e.g. maternal diet, smoking, and exposure to stressful events).  
 
Methods 
Sample 
The Epigenetic Pathways to Conduct Problems Study consists of a subsample of youth 
(n=321; 50% female) drawn from the Avon Longitudinal Study of Parents and Children 
(ALSPAC) and partially overlapping with a larger study of DNA methylation, the Accessible 
Resource for Integrated Epigenomics Studies (ARIES, www.ariesepigenomics.org.uk;  
Relton et al., 2015). Specifically, children were included if they (i) have available measures 
of DNAm at two or more time points and (ii) follow previously established trajectories of 
conduct problems between 4 and 13 years of age (see measures section below; E. D. Barker 
& Maughan, 2009). Children in this study were white Caucasian (six removed from analyses 
due to missing ethnicity data).  
 ALSPAC is an ongoing epidemiological study of 14,541 pregnant women resident in 
Avon, UK with expected dates of delivery 1st April 1991 to 31st December 1992.  Of these 
initial pregnancies, there was a total of 14,676 fetuses, resulting in 14,062 live births and 
13,988 children who were alive at 1 year of age (Fraser et al., 2013). When compared to 1991 
National Census Data, the ALSPAC sample was found to be broadly similar to the UK 
population as a whole (Boyd et al., 2013). The study website contains details of all the data 
that is available: http://www.bris.ac.uk/alspac/researchers/data-access/data-dictionary. Ethical 
approval for the study was obtained from the ALSPAC Law and Ethics Committee and the 
Local Research Ethics Committees.  
Measures 
Conduct Problems 
CP trajectories were previously identified and validated in the whole ALSPAC sample using 
growth mixture models based on repeated measures of the Strengths and Difficulties 
Questionnaire ‘conduct problems’ subscale (ages 4,7,8,10,12,13; SDQ; Goodman, 2001), 
with boys and girls modeled in the same trajectories (E. D. Barker & Maughan, 2009). The 
original analysis identified four CP trajectories: (i) an early-onset persistent (EOP; 9%) group 
of children, who show high levels of CP early on and remain high across time; (ii) a 
childhood-limited (CL; 15%) group who also show an early-onset of CP, but desist around 
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adolescence; (iii) an adolescent-onset group who only show CP behaviors later on (AO; 
12%); and (iv) a low CP group, who maintain low levels of CP throughout (Low CP; 64%). 
The percentage of youth identified in the CP trajectories in ALSPAC is consistent with 
reported prevalence estimates in the general population (4-20%; Egger & Angold, 2006; 
Kim-Cohen et al., 2003). In contrast to the overall ALSPAC sample, our epigenetic 
subsample featured a near equal number of youth in each trajectory, and was therefore 
enriched for CP (EOP: n = 91, 28%; CL: n = 83, 26%; AO: n = 61, 19%; Low CP: n = 86, 
27%). In this study, early-onset CP youth were defined as youth who follow either an EOP or 
CL trajectory.  The adolescent-onset (AO) group was excluded from the main analyses for 
two reasons. First, although AO and Low children appear phenotypically similar in CP levels 
during the developmental period under investigation, they have been shown to differ in levels 
of environmental risk exposure and temperamental features (Barker & Maughan, 200), so that 
we decided against combining AOs within the Low (i.e. typical) group. Second, we did not 
include AOs as a separate comparison group in the epigenome-wide analyses due to concerns 
over statistical power and multiple testing burden resulting from the increase in number of 
comparisons. 
DNA Extraction and Methylomic Profiling 
DNA was obtained from cord blood samples at birth. 500ng genomic DNA was bisulfite 
converted using an EZ-DNA methylation kit (Zymo Research, Orange, CA, USA) and 
DNAm quantified using the Illumina HumanMethylation450 BeadChip (450K array; 
Illumina, USA) with arrays scanned using an Illumina iScan (software version 3.3.28). The 
Illumina 450K array comprises >485,000 probes, each quantifying DNAm at a specific CpG 
site, covering 99% of Reference Sequence (RefSeq) genes, with an average of 17 CpG sites 
per gene region (distributed across promoter, 5’UTR, first exon, gene body and 3’UTR 
regions). The BeadChip covers 96% of CpG islands, with additional coverage in island 
shores and their flanking regions. Initial quality control of data generated was conducted 
using GenomeStudio (version 2011.1) to determine the status of staining, extension, 
hybridization, target removal, bisulfite conversion, specificity, non-polymorphic and negative 
controls. Furthermore, multiple checks for sample mismatch were carried out to ascertain that 
all cord blood samples in the study reflected infant DNA as opposed to maternal DNA. 
Specifically, samples were checked by calculating concordance with (i) GWA data from the 
same participants, (ii) SNP probes on the Illumina 450k array across mother and child, and 
(iii) sex.  Data were quantile normalized using the dasen function as part of the wateRmelon 
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package (wateRmelon_1.0.3; Pidsley et al., 2013) within the R statistical analysis 
environment and batch corrected using the ComBat package (Johnson, Li, & Rabinovic, 
2007). Probes previously reported to hybridize to multiple genomic regions or containing a 
SNP at the single base extension site were removed from subsequent analyses (Chen et al., 
2013; Price et al., 2013), in addition to the 65 SNPs used for sample identification on the 
array (total probes removed 72,067). For each probe, DNAm levels were indexed by beta 
values – i.e. the ratio of methylated signal divided by the sum of the methylated and 
unmethylated signal (M/M+U). 
Prenatal environment 
Multiple environmental influences were included that have been previously linked to early-
onset CP, including maternal prenatal diet, smoking, alcohol use and exposure to stressful 
events (E. D. Barker & Maughan, 2009).   Information on dietary patterns was drawn from 
maternal ratings of the Food Frequency Questionnaire at 32 week gestation, where factor 
scores of ‘healthy’ (i.e. high on fish, non-meat protein and vegetables) and ‘unhealthy’ (i.e. 
high on processed and junk food) diet were extracted using confirmatory factor analysis, both 
of which showed acceptable model fit (for full details, see E. D. Barker, Kirkham, Ng, & 
Jensen, 2013). Maternal smoking and alcohol use during the first trimester of pregnancy were 
measured via maternal ratings, using a yes/no binary variable for smoking, and a 4-point 
scale for alcohol use (‘never’ to ‘daily’). With regards to stress exposure, we included 
cumulative risk scores of prenatal (18 to 32 weeks) adversity, based on 56 dichotomous items 
from the Life Events inventory (adapted in ALSPAC based on the work of Brown et al., 1973 
and Barnett et al.,1983) and the Family Adversity Index (Wolke, Steer & Bowen, 2004). 
Briefly, items were organized into four conceptually distinct but related risk domains, and 
summed to create the following cumulative scores: (i) life events (22 items; e.g. death in 
family, accident); (ii) contextual risks (16 items; e.g. poor housing, financial problems); (iii) 
maternal risks (10 items; e.g. psychopathology, criminal behavior); and (iv) interpersonal 
risks (8 items; e.g. partner abuse, family conflict). The full list of items contained in these 
cumulative scores is provided in online supplement OS1, and further information is available 
elsewhere (Cecil et al., 2014b; Rijlaarsdam et al., 2016b).  
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Statistical Analyses 
All analyses were performed within R (version 3.0.1; R Core Team, 2014) on DNAm data 
regressed for sex and cell-type proportions (CD8 T lymphocytes, CD4 T lymphocytes, 
natural killer cells, B lymphocytes, monocytes), estimated using the reference-based 
approach detailed in Houseman et al. (2012).  
Step 1: Are there differences in neonatal patterns of DNAm between children who go on to 
develop early-onset vs low CP? 
First, a methylome-wide association analysis was performed using the CpGAssoc package 
(Barfield, Kilaru, Smith, & Conneely, 2012) to identify DNAm sites at birth that differentiate 
children who go on to develop early-onset (i.e. EOP and CL) vs low CP. False discovery rate 
(FDR) correction was implemented across all probes (i.e. genome-wide significance 
threshold set at q < 0.05). Effect sizes were calculated and interpreted following Cohen’s 
guidelines, where an effect of 0.20 represents a small effect, and effect of 0.50 is a medium 
effect and an effect of 0.80 is a large effect (Cohen, 1988). 
 Genome-wide significant loci were then uploaded to the UCSC genome browser 
(GRCh37/hg19 assembly; Kent et al., 2002) to explore their potential functional relevance, 
by comparing their genomic location to that of key regulatory elements recorded in the 
Encyclopedia of DNA Elements (ENCODE) database (http://genome.ucsc.edu/ENCODE/). 
These included (i) transcription factor binding sites, i.e. DNA regions where one or more 
specific proteins responsible for regulating transcription bind to (data generated on 161 
transcription factors in 91 cell types via ChIP-seq); (ii) DNase I hypersensitivity clusters, 
which tend to coincide with regulatory regions of the gene and indicate an open chromatin 
state that facilitates transcription (based on data from 125 cell types), and (iii) histone marks, 
i.e. chemical modifications that influence how tightly packaged the DNA is around histone 
protein, thereby regulating how accessible DNA is for transcription (data available for seven 
cell types; however, given that DNAm patterns can be tissue specific, we only selected here 
the three cell-types that are most relevant to cord blood; i.e. blood [GM12878, K562] and 
umbilical vein endothelial [HUVEC] cells). To identify enriched biological pathways, we 
also analyzed probes that were significant at p<0.001 using an optimized gene ontology 
method that corrects for multiple potential confounds, including background probe 
distribution and gene size (see OS2). 
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Step 2: Within the early-onset group, do these DNAm sites also differentiate children who 
will persist vs desist in CP over time? 
As a second step, we examined whether the identified DNAm sites may help to explain 
heterogeneity in developmental trajectories within the early-onset CP group. Specifically, we 
used one-way Analysis of Covariance (ANCOVA) models to test whether DNAm levels 
across the sites identified in Step 1 also differentiate early-onsets who will go on to follow a 
persisting (i.e. EOP) vs desisting (i.e. CL) trajectory of CP behaviour over time, controlling 
for sex and cell-type proportions.  
Step 3: Are the identified DNAm sites associated with genetic and environmental factors? 
As a final step, we explored potential genetic and environmental factors that may influence 
the DNAm sites associated with early-onset CP (i.e. identified in Step 1). As our sample was 
underpowered to directly examine genetic polymorphisms (i.e. SNPs) affecting DNAm, we 
used the mQTLdb resource (http://www.mqtldb.org/) to search for known methylation 
quantitative trait loci (mQTLs) associated with our DNAm sites of interest. The mQTLdb 
database contains the results of a large-scale study based on the ARIES sample in ALSPAC 
(from which our subsample is derived), characterizing genome-wide significant cis effects 
(i.e. SNP within ±1000 base pairs of the DNAm site) and trans effects (i.e. ±1 million base 
pairs) on DNAm levels across Illumina 450k probes at five different life stages, including 
cord blood DNAm at birth (Gaunt et al., 2016). Here, we searched for mQTLs based on 
results from the conditional Genome-wide Complex Trait Analysis (GCTA), which was used 
to identify mQTLs with the most representative, independent effect on each DNAm site in 
order to account for linkage disequilibrium (Gaunt et al., 2016). With regards to 
environmental influences, we examined associations between DNAm levels in the identified 
sites and prenatal exposures (i.e. maternal diet, smoking, alcohol use and stressful events) 
using Pearson’s bivariate correlations. Again, the significance threshold was set at an FDR-
corrected level of q<0.05 to adjust for multiple comparisons.  
Results 
Neonatal DNA methylation and early-onset CP 
The Q-Q plot and Manhattan plot for the epigenome-wide association analysis at birth 
are displayed in Figure 1 (A-B). Table 1 shows the seven differentially methylated sites (q-
value < 0.05) between early-onset vs low CP groups, as identified via our genome-wide 
analysis. Group differences were medium to large in effect size based on Cohen’s guidelines 
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(d = 0.66 – 0.84), and ranged from 4% to 8% in terms of mean DNAm difference. Of note, all 
seven sites remained differentially methylated after additionally adjusting for gestational age. 
DNAm levels across these sites were all significantly inter-correlated (both positive and 
negative correlations observed; see OS3). Three of the sites had genic annotations (Figure 
1C): (i) cg02503763, located in the promoter regulatory region of MGLL, a gene implicated 
in endocannabinoid signaling and nociperception (Iwasaki, Ishiguro, Higuchi, Onaivi, & 
Arinami, 2007); (ii) cg21579239, annotated to the 5'UTR region of TTBK2, a gene involved 
in tau protein phosphorylation, of which mutations have been linked to neurodegenerative 
disorders (Liao, Yang, Weng, Kuo, & Chang, 2015); and (iii) cg16006965, located in the 
promoter regulatory region of GCET2, a gene implicated in immune function (Pan et al., 
2007). The other four differentially methylated sites identified at birth were distal to 
annotated transcripts (see OS4 for boxplots): cg12628061 located between AK127270 (-
407kb) and PPAP2B (-507kb), cg02131674 located closest to BASP1 (-123kb), cg15384400 
located between ARAP2 (-12kb) and DTHD1 (+26kb), and cg07128473 located between 
TRPS1 (-210kb) and EIF3H (+876kb). In all cases – except for probe cg15384400 – 
methylation of these sites was lower in the early-onset vs low CP groups.  These seven sites 
were then viewed in Genome Browser for functional characterization, based on ENCODE 
data on regulatory elements. Four of the DNAm loci coincided with transcription factor 
binding sites, including MGLLcg02503763 and GCET2cg16006965, and implicated a number of 
shared transcription factors, including MAX (4/4 loci), POLR2A, RUNX3 and EP300 (3/4 
loci). The majority of DNAm sites also overlapped with histone marks (6/7 loci) and DNAse 
I hypersensitive clusters (4/7 loci), suggesting that they are located in genomic regions that 
are likely to play regulatory roles in transcription. Gene ontology analysis (nprobes = 1101; 
ngenes = 758) further indicated that DNAm sites (at birth) that differentiate between CP groups 
are annotated to genes involved in a range of biological processes, including regulation of fat 
cell differentiation and immune system process, response to epinephrine and wounding, as 
well as forebrain generation of neurons and CNS neuron differentiation (2.95E-15 <p< 
6.66E-05, Figure 1D).  GO results for the top 20 enriched biological pathways (including 
those displayed in Figure 1D) are provided in OS5.  
******************************** Table 1 ******************************** 
******************************** Figure 1 ******************************* 
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In light of the above findings, we conducted two follow-up analyses to further investigate the 
relationship between DNAm at birth and early-onset CP. 
Methylomic variation in MGLL, TTBK2 and GCET2.  
Our genome-wide analyses indicated that three of the seven sites identified as differentiating 
early-onset vs low CP children were annotated to genes, including MGLL, TTBK2 and 
GCET2 (one site each). As an additional step, we examined whether any other probes in the 
vicinity of these genes associated with early-onset CP at a nominal level. While none of the 
other probes in TTBK2 (ntotal = 10 probes) or GCET2 (ntotal = 19 probes) associated with early-
onset vs low CP (p > 0.05), four additional probes in MGLL were differentially methylated 
between groups, including another probe in the TSS1500 region (cg02116612; p = 1.95E-05; 
significant at gene-level Bonferroni correction: 0.05/26 total annotated probes = 0.002) and 
three probes in the gene body region (cg14476212, p = 0.028; cg10319942, p = 0.034; and 
cg15694422, p = 0.048). The location of these probes and their relationship to ENCODE 
regulatory elements is displayed in Figure 2 (for more detailed information, see OS6). Of 
note, two of these additional probes correlated significantly with the genome-wide significant 
site MGLLcg02503763 – including a stronger association with the most proximal probe in the 
TSS1500 region (cg02116612; r = 0.46, p = 6.04E-15) and a weaker association with one of 
the probes in the gene body (cg10319942; r = 0.15, p = 0.01).  
******************************* Figure 2 ******************************** 
Methylomic variation in candidate genes for conduct problems.  
As shown in Table 1, none of the genome-wide significant loci identified resided in 
‘traditional’ candidate genes for CP. In order to maximise comparability with existing 
molecular studies, we carried out a follow-up analysis to investigate DNAm variation in the 
vicinity of genes that have been previously implicated in CP-relevant phenotypes. The 
selection of candidate genes was informed by a recent systematic review (Waltes, 
Chiocchetti, & Freitag, 2015) and meta-analysis (Pappa et al., 2015) of genetic influences on 
aggression. Specifically, we selected a total of 15 genes (ntotal = 387 probes), across (i) 
dopaminergic (MAOA [14 probes], COMT [22 probes], SLC6A3 [52 probes],DRD2 [22 
probes], DRD4 [21 probes]); (ii) serotonergic (SLC6A4 [14 probes], HTR1A [14 probes], 
HTR2A [25 probes], TPH1 [4 probes], TPH2 [18 probes]); and (iii) neuroendocrine and 
neurodevelopmental pathways (NR3C1 [35 probes], FKBP5 [32 probes], AVP [14 probes], 
OXTR [17 probes], BDNF [73 probes]). As done by Weder et al. (2014), we used a gene-level 
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Bonferroni correction for these hypothesis-driven analyses, correcting for the total number of 
probes within each gene.  
In total, 12% of probes were differentially methylated between groups at a nominal 
significance threshold (p<0.05), with at least one probe associating with early-onset CP for 
each gene (see OS7). However, only 4 of these loci survived gene-level Bonferroni-
correction (see Table 2), including sites annotated to BDNF (cg01225698, cg18354203), 
FKBP5 (cg07061368) and the MAOA promoter region (i.e. TSS200; cg05443523). Effect 
sizes for these loci were small (d = 0.44-0.49), and mean group DNAm differences ranged 
from 1% to 3%. Based on ENCODE data, all four probes coincided with transcription factor 
binding sites and histone marks, with two of the probes additionally coinciding with DNase I 
hypersensitivity clusters. As with the loci identified via our epigenome-wide analysis, these 
four probes remained significantly associated with CP trajectory after controlling for 
gestational age.  
******************************** Table 2 ******************************** 
Comparison of top DNAm probes between early-onsets who persist vs desist in CP 
Within the early-onset CP group, none of the DNAm sites identified in the previous step (i.e. 
7 FDR-corrected genome-wide significant loci and 4 Bonferroni-corrected loci from the 
candidate gene follow-up analyses) were found to differentiate children who will go on to 
follow a persisting vs desisting trajectory of conduct problems over time (p > 0.05, see OS8 
for full results).  This lack of differences suggest that, while methylomic variation at birth 
prospectively associates with an early-onset of CP (i.e. distinguishing between high vs low 
CP early in childhood), this variation is not likely to contribute towards heterogeneity in 
developmental trajectories of conduct problems observed within early-onset children.  
 
Potential relevance of genetic and in utero environmental influences on the identified    
DNAm sites 
The 11 DNAm sites associated with early-onset CP were carried forward to explore 
associations with potential genetic and environmental influences. Based on mQTLdb search, 
we found that none of the identified loci were associated with cis or trans mQTLs, suggesting 
that DNAm levels across these sites are not likely to be heavily influenced by known genetic 
polymorphisms. Bivariate correlations between the DNAm loci and prenatal exposures are 
shown in Table 3, controlling for sex and cell-type. Of the 11 probes examined, 7 were 
nominally correlated with one or more exposures (p < 0.05), but none of these associations 
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remained significant after multiple correction (q > 0.05). The majority of associations 
involved maternal smoking and alcohol use during the first trimester of pregnancy. Around 
half of associations identified remained significant after additionally controlling for all other 
prenatal exposures (i.e. unique association, see Table 3).  
******************************** Table 3 ******************************** 
 
Discussion 
This is the first study to investigate the epigenetic landscape of early-onset conduct problems, 
using a prospective design.  The study offers a number of strengths, including the 
examination of genome-wide data collected prior to the emergence of CP symptoms, the 
inclusion of the largest epigenetic CP sample to date, allowing for adequately-powered group 
comparisons (Tsai & Bell, 2015), as well as the integration of environmental, DNAm and 
phenotypic data.  We highlight here three key findings: (i) methylomic variation across 
multiple loci at birth differentiated children who go on to develop early-onset vs low CP; (ii) 
DNAm levels across these loci were comparable for early-onsets who persist vs desist in CP 
over time; and (iii) several of the identified loci showed suggestive associations with prenatal 
exposures, while none were linked to known genetic mQTLs. 
Genome-wide findings point to the potential importance of methylomic variation at birth 
The use of a genome-wide, hypothesis-free approach enabled us to identify novel loci for CP, 
pointing to potential avenues for future investigation.  Specifically, we found that seven loci 
at birth prospectively differentiated CP groups, showing a moderate-to-large effect size 
difference between children who go on to develop early-onset vs low CP. Functional 
characterization using ENCODE data indicated that the majority of the identified sites 
coincided with regulatory elements that play a key role in gene expression, including 
transcription factor binding sites, DNase I hypersensitivity clusters (i.e. regions of open 
chromatin) and histone marks. Six of the loci were significantly hypomethylated in early-
onset vs low CP children, and three were annotated to genes. Of these, MGLL encodes a 
serine hydrolase that converts monoacylglycerides to free fatty acids and glycerol and acts as 
a major endocannabinoid metabolic enzyme (Iwasaki et al., 2007). Interestingly, previous 
studies have shown that MGLL activity associates with substance abuse (Hopfer et al., 2007), 
which is highly comorbid with CP (McAdams, Salekin, Marti, Lester, & Barker, 2014). 
Furthermore, CB1 cannabinoid receptor function (modulated indirectly by MGLL via 2-
Arachidonoylglycerol [2-AG] activation) has been shown to mediate aggression in animal 
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knockout studies (Rodriguez-Arias et al., 2013). Together, these findings support a link 
between MGLL function and CP-relevant phenotypes, although more work will be needed to 
delineate the functional effects of MGLL methylation on broader endocannabinoid signaling 
and downstream consequences on behavior. We do note that in follow-up analyses, a number 
of additional DNAm sites associated with early-onset CP across the promoter region and 
gene body of MGLL, as well as coinciding with key regulatory elements, which further 
supports a link between epigenetic regulation of this gene and CP.  
Another DNAm site that showed CP-related DNAm at birth was annotated to TTBK2. 
This gene is highly expressed in subcortical brain structures (e.g. cerebellum, hippocampus) 
and is involved in the phosphorylation of tau and tubulin, two key microtubule stabilization 
proteins that are robustly associated with multiple nervous system pathologies, including 
Alzheimer’s disease (Liao et al., 2015). Although we are not aware of studies directly 
investigating the link between TTBK2 and CP-relevant phenotypes, it is noteworthy that 
associations between levels of tau phosphorylation in the brain and aggressive behavior have 
been previously reported in patients with Alzheimer’s disease (e.g., Guadagna, Esiri, 
Williams, & Francis, 2012). As such, it will be of interest in future to examine whether 
TTBK2 methylation may contribute to early-onset CP via microtubule alterations in the brain.  
The third gene identified, GCET2, plays a role in immune processes, including 
cytokine function (Pan et al., 2007). While an increasing number of studies has documented a 
link between inflammation and psychiatric phenotypes, including childhood aggression (e.g. 
Provençal et al., 2013), little is known about the function of this gene in relation to CP. It is 
interesting; however, that a genome-wide study recently identified GCET2 expression levels 
as a potential biomarker for antidepressant treatment response (Hennings et al., 2015), 
pointing to a potential role of this gene in mood regulation.    
DNA methylation of candidate genes: Maximizing comparability with previous studies  
Consistent with what has been previously reported in the psychiatric epigenetic literature (e.g. 
Cecil, Walton, & Viding, 2015), we found that none of the DNAm sites identified via our 
hypothesis-free, epigenome-wide analysis were annotated to genes that are typically 
examined in hypothesis-driven, candidate gene studies. In order to maximize comparability 
with existing molecular studies, we carried out an additional analysis focusing on DNAm in 
the vicinity of 15 genes that have been extensively investigated in relation to CP and related 
phenotypes (e.g. aggression; Pappa et al., 2015; Waltes et al., 2015). It is important to note 
that these studies have primarily focused on genetic (as opposed to epigenetic) contributions 
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to CP, so that a direct test of replication was not possible. Rather, this follow-up analysis was 
designed to explore the potential role of these genes in early-onset CP from an epigenetic 
perspective. Although none of the DNAm sites annotated to candidate genes passed genome-
wide correction, sub-threshold associations were identified across three genes, including 
BDNF (two probes), MAOA (one probe) and FKBP5 (one probe). Of note, effect sizes were 
small but not trivial (>0.44), suggesting that these DNAm differences may hold relevance for 
understanding biological vulnerability for early-onset CP.  
BDNF encodes for a neutrophic protein that performs a wide range of functions, 
including regulation of neurodevelopment, synaptic plasticity and mood. While a link 
between aggression and BDNF activity has been documented by multiple lines of evidence – 
including findings from genetic, knock-out, endocrine and pharmacological studies (Waltes et 
al., 2015) – this is the first report, to our knowledge, of an association with BDNF DNAm 
levels. The role of MAOA activity on aggression has also received widespread attention from 
both the animal and human literature, due to its key role in the degradation of amine 
neurotransmitters in the brain, including dopamine, norepinephrine and serotonin (Nelson & 
Trainor, 2007). Consistent with our findings, a recent study reported that hypermethylation of 
the MAOA promoter region (with an average DNAm difference between groups of 3% - the 
same as observed in the present study) was associated with antisocial personality disorder in a 
forensic population, as well as decreased gene expression and dysregulation of serotonin 
blood serum levels (Checknita et al., 2015). Interestingly, MAOA promoter DNAm in blood 
has also been shown to robustly predict MAOA enzymatic activity in the brain (Shumay, 
Logan, Volkow, & Fowler, 2012), suggesting that peripheral MAOA DNAm status may be a 
promising biomarker for functional levels in live central tissue, which is most relevant to CP. 
Finally, the FKBP5 gene, which codes a co-chaperone of the glucocorticoid receptor that 
regulates its sensitivity, has been extensively investigated for its role in mediating stress, 
hormonal and immune responses to adverse experiences, particularly in the context of gene-
environment interactions (Zannas & Binder, 2014).  For example, FKBP5 polymorphisms 
have been found to interact with childhood trauma (e.g. maltreatment) to predict a range of 
psychiatric outcomes, including childhood aggression (Bryushkova et al., 2016). While 
emerging evidence suggests that FKBP5 methylation may mediate these observed GxE 
interactions (Zannas, Wiechmann, Gassen, & Binder, 2015), more work is needed to 
characterize its relevance to CP behaviour.   
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Heterogeneity in developmental trajectories within the early-onset CP group 
Whereas the identified DNAm sites at birth differentiated children who develop early-onset 
vs low CP, these same sites did not further discriminate between early-onsets who go on to 
follow a persisting (i.e. EOP) vs desisting (i.e. CL) trajectory of CP into adolescence. This 
lack of associations may reflect a number of possibilities. For example, it is possible that, at 
birth, EOP and CL children may be phenotypically and biologically similar. In other words, 
while they may both be at increased risk for early-onset CP relative to typical children, it may 
not yet be possible to separate those who will persist vs desist in CP behavior over time. 
Given that EOP vs CL children start to diverge in levels of CP around late childhood and 
predict different outcomes in adulthood (David P Farrington, Gallagher, Morley, Ledger, & 
West, 1988; Terrie E Moffitt, Caspi, Harrington, & Milne, 2002), it will be of interest in 
future to extend epigenetic analyses later in development, so as to investigate whether these 
behavioural differences may coincide with underlying epigenetic differences. In addition, the 
examination of DNAm at later time points would enable one to test potential associations 
with postnatal environmental influences, which are likely to play an important role in the 
divergence between EOP and CL trajectories. It is also possible that statistically, our analyses 
were underpowered to examine within-group differences in DNAm patterns among the early-
onset group. Larger longitudinal studies will be needed in future to enable a more fined-tuned 
comparison of DNAm patterns between EOP and CL children across multiple developmental 
periods.  
Genetic and prenatal influences on DNAm patterns associated with early-onset CP  
As a final step, we investigated whether DNAm loci at birth that differentiated between early-
onset vs low CP children (both at the genome-wide and candidate-gene level) were also 
associated with potential genetic and environmental influences relevant to CP (E. D. Barker 
& Maughan, 2009; Salvatore & Dick, 2016). Based on findings from a large-scale study of 
genetic effects on DNAm (Gaunt et al., 2016), we found that none of the identified loci 
associated with known cis or trans mQTLs. While this suggests that the identified loci were 
unlikely to be heavily influenced by genetic structure, it is important to note that the 
heritability of DNAm patterns is greater than what can currently be explained using known 
mQTLs (Gaunt et al., 2016). As such, it is still possible that the identified loci may have been 
influenced by polygenic effects, involving many mQTL that each explain too little variance 
in isolation to be detected with currently available samples.  
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With regards to environmental influences, we identified suggestive associations 
between the identified DNAm sites and prenatal exposures. Of note, we found that proximal 
exposures (e.g. maternal smoking and alcohol use) correlated with DNAm more strongly than 
more distal exposures (e.g. life events). Albeit preliminary, these findings are consistent with 
previous studies showing that DNAm is associated with environmental influences (e.g. Lewis 
& Olive, 2014), with smoking-related effects, in particular, being amongst the most replicated 
across epigenetic studies (Gao, Jia, Zhang, Breitling, & Brenner, 2015). For example, we 
found that prenatal smoking correlated with hypomethylation of the MGLL probe, which in 
turn prospectively associated with early-onset CP. This is of interest given that activity of this 
gene has been shown to influence nicotine withdrawal in animals and humans (Muldoon et 
al., 2015), as well as interacting with environmental exposures to predict cannabis 
dependence symptoms and amygdala function (Carey et al., 2015). However, it is important 
to note that the associations identified in the present study were based on correlational 
analyses and did not survive multiple correction. Consequently, they should be interpreted 
with caution and considered more as well-grounded hypotheses for further examination in 
larger longitudinal studies.  
Limitations 
Findings should be interpreted in light of a number of limitations. First, because results from 
this study were based on DNAm collected from peripheral samples, the extent to which they 
may be tissue-specific is unclear. More research will be needed to assess the relevance of the 
identified DNAm sites to brain tissue, as well as characterizing their potential role in CP-
related brain-based phenotypes. Furthermore, because we did not have access to RNA, 
functional characterization of the identified loci was performed using recorded ENCODE 
data.  However, integration of transcriptomic data will mark an important step toward 
establishing the functional significance and downstream effects of the observed DNAm 
changes. Second, the current study was based on a community sample of children with 
relatively low rates of CP. In future, it will be important to replicate our findings in high-risk 
populations who show more severe externalising problems (e.g. young offenders, psychiatric 
inpatients). Furthermore, the use of a larger number of cases vs controls will make it possible 
to examine potential moderators in the relationship between DNAm and early-onset CP (e.g. 
sex). Finally, although we used a prospective design where DNAm was collected prior to the 
emergence of CP symptoms, the results from the study are correlational and cannot be taken 
to reflect causal pathways. As such, findings should be considered as hypothesis-generating 
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and in need of replication. In future, the application of advanced inference methods (e.g. two-
step Mendelian randomization; Pingault, Cecil, Murray, Munafò & Viding, 2016; Relton & 
Davey Smith, 2012), will offer unique opportunities to establish causal relationship between 
prenatal environmental risk, DNAm and CP.  
Conclusion 
In this study, we find that DNA methylation at multiple loci at birth prospectively associated 
with early-onset vs low conduct problems. These findings highlight the neonatal period as a 
potentially important window of biological vulnerability for conduct problems, as well as 
pinpointing novel potential risk markers for future investigation. Suggestive evidence of 
associations between the identified loci and prenatal exposures also lend preliminary support 
for a link between the early environment, DNA methylation and the development of early-
onset conduct problems.  
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Figure legends: 
Figure 1. Methylomic variation at birth prospectively associated with early-onset vs low 
conduct problems in childhood. Epigenome-wide associations between DNA methylation at 
birth and early-onset vs low conduct problems (CP), including Q-Q plot (A), Manhattan plot 
(B) and scatterplots of the top 3 differentially methylated sites with genic annotations (C). 
Significantly enriched biological processes at birth are shown in (D), based on gene ontology 
(GO) analysis of genes annotated to probes that associate with early-onset vs low CP (p < 
0.001). Circles represent GO terms that survive FDR-correction and contain at least two 
genes. The X axis represents -log(10) p-values. The opacity of the circles indicates level of 
significance (darker = more significant). The size of the circles indicates the percentage of 
genes in our results for a given pathway compared to the total number of genes in the same 
pathway (i.e. larger size = larger %).  
  
Figure 2. Functional characterization of MGLL DNA methylation sites associated with 
early-onset conduct problems. Expanded views from the UCSC genome browser of the 
MGLL gene showing the position of the DNAm sites associated with early-onset CP relative 
to ENCODE regulatory elements. Track numbers are displayed on the left-hand site, and 
represent the following (1) genomic positon of MGLL in chromosome 3; (2) genomic 
coordinates and scale; (3) location of all Illumina 450k probes that map onto the MGLL gene 
(n = 26); (4) location of differentially methylated probes associated with early-onset vs low 
conduct problems (n = 5). These are highlighted in blue to facilitate comparison with the 
regulatory elements displayed in lower tracks (track 6-8). In red is the probe that survived 
genome-wide correction (MGLLcg02503763; all other probes significant at p<0.05); (5) 
schematic representation of the MGLL gene; (6) location of transcription factors (based on 
ChIP-seq data from 91 cell types), where darker shades indicate a stronger signal occupancy; 
(7) DNaseI hypersensitivity clusters (based on ChIP-seq data from 125 cell types), where 
darker shades also indicate a stronger signal; and (8) levels of enrichment of three histone 
marks (H3K27Ac, H3K4Me1, and H3K4Me3) across three cell-types, including blood 
(GM12878 [red], K562 [purple]) and umbilical vein endothelial (HUVEC [blue]) cells.  
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Table 1. DNA methylation sites at birth that differentiate early-onset vs low CP children (genome-wide significance; q<0.05)  
 
 
 
 
 
 
 
 
 
 
 
a Arrows represent the direction of methylation differences, where  indicates higher methylation levels in early-onset vs low CP children, while 
 indicates lower methylation levels in early-onset vs low CP children. Cohen’s d: .20 is a small effect size, .50 is a medium effect size, .80 is a 
large effect size.  
 
 
 
 
 
 
Probe Gene Chr Genomic 
location 
Position p-value q-value 
(FDR) 
Direction Early-onset 
CP Mean 
Low CP 
Mean 
% Diff Cohen's d 
cg12628061 -- 1 -- 56453730 2.47E-09 1.00E-03 ↓ 0.77 0.81 4% 0.84 
cg02131674 -- 5 -- 17341065 1.64E-08 3.00E-03 ↓ 0.77 0.81 4% 0.78 
cg15384400 -- 4 -- 36257279 5.09E-08 7.00E-03 ↑ 0.26 0.21 5% 0.79 
cg07128473 -- 8 -- 116891579 1.00E-07 0.01 ↓ 0.83 0.86 3% 0.76 
cg02503763 MGLL 3 TSS1500 127542386 1.23E-07 0.01 ↓ 0.38 0.46 8% 0.73 
cg21579239 TTBK2 15 5'UTR 43211292 1.40E-07 0.01 ↓ 0.74 0.78 4% 0.73 
cg16006965 GCET2 3 TSS1500 111852325 7.85E-07 0.04 ↓ 0.53 0.6 7% 0.66 
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Table 2. Candidate gene follow-up: Loci that differentiate between early-onset and low CP children (gene-level Bonferroni correction) 
N.b. Arrows represent the direction of methylation differences, where ↑ indicates higher methylation levels in early-onset vs low CP children, 
while ↓ indicates lower methylation levels in early-onset vs low CP children. Cohen’s d: .20 is a small effect size, .50 is a medium effect size, .80 
is a large effect size.  
 
 
 
 
Probe Chr Genomic 
Location 
Position p-value q-value 
(genome-wide) 
Bonferroni 
(gene-level) 
Direction Early-onset 
CP Mean 
Low      
CP Mean 
% Diff Cohen's d 
BDNF                       
  cg01225698 11 Body; TSS1500 27742355 3.44E-04 0.30 Significant ↑ 0.16 0.15 1% 0.47 
  cg18354203 11 Body; 5'UTR 27696004 4.97E-04 0.33 Significant ↓ 0.72 0.75 3% 0.49 
FKBP5                       
  cg07061368 6 5'UTR 35631736 9.96E-04 0.37 Significant ↓ 0.81 0.83 2% 0.44 
MAOA                       
  cg05443523 X TSS200 43515213 1.17E-03 0.38 Significant ↑ 0.36 0.33 3% 0.44 
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Table 3. Associations between prenatal environmental exposures and loci that are differentially methylated in early-onset vs low CP children. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Prenatal environment 
  Healthy                   
diet 
Unhealthy             
diet 
Maternal  
smoking 
Maternal alcohol 
use 
Life                         
events 
Contextual 
risks 
Parental 
risks 
Interpersonal 
risks 
Genome-wide analyses                 
    cg12628061  0.09 -0.06 -0.16 (p = 0.01)a 0.17 (p = 0.01)
 
 0.09 0.02 -0.09 0.07 
    cg02131674 0.09 -0.07 -0.10 0.10 0.10 0.05 -0.09 0.04 
    cg15384400 -0.07 0.07 0.09 0.00 -0.05 -0.01 0.11 0.05 
    cg07128473 0.14 (p = 0.03)a -0.08 -0.10 0.12  0.05 0.05 -0.07 0.06 
    cg02503763 (MGLL) 0.03 -0.01 -0.14 (p = 0.02) 0.13 (p = 0.03)a -0.05 -0.04 -0.08 -0.02 
    cg21579239 (TTBK2) 0.08 -0.07 -0.16 (p = 0.01) 0.09 0.09 0.04 -0.12 0.02 
    cg16006965 (GCET2) 0.05 0.01 -0.10 0.17 (p = 0.01) 0.07 0.09 -0.07 0.04 
Candidate gene follow-up analyses             
    cg01225698 (BDNF)  -0.10 0.08 0.05 -0.03 -0.02 0.04 0.03 0.02 
    cg18354203 (BDNF)  0.06 -0.12 -0.09 0.00  -0.01 -0.03 -0.06 0.07 
    cg07061368 (FKBP5) 0.00 -0.03 -0.08 0.20 (p = 0.001)a 0.11 0.08 -0.03 0.10 
    cg05443523 (MAOA) -0.09 0.10 0.03 -0.09 -0.13 (p = 0.001)a -0.02 -0.01 -0.04 
 
N.B. All associations control for sex and cell-type. a Association remains significant after additionally controlling for other exposures, p<0.05 
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Figure 1. Methylomic variation at birth prospectively associated with early-onset vs low 
conduct problems in childhood 
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Figure 2. Functional characterization of MGLL DNA methylation sites associated with early-
onset conduct problems 
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List of supplementary materials: 
OS1. List of items included in the prenatal cumulative adversity measures  
OS2.  Optimized gene ontology (GO) method. 
OS3.  Intercorrelations between DNAm levels across the identified sites 
OS4. Boxplots of mean methylation differences between CP groups across four genome-
wide significant probes (q<0.05) that are distal to annotated transcripts. 
OS5. Top 20 enriched biological processes at birth differentiating early-onset vs low CP 
children based on GO pathway analysis 
OS6. Detailed functional characterization of MGLL DNA methylation sites associated with 
early-onset conduct problems 
OS7 Candidate gene follow-up analyses 
OS8. Comparison of DNAm levels across the identified loci between early-onset children 
who persist (i.e. EOP) vs desist (i.e. CL) in conduct problems over time. 
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OS1. List of items included in the prenatal cumulative adversity measures 
  N. items Range M (SD) Items 
 
Life events 22 0-8 2.48 (1.71) Your partner died  You lost your job  
        One of your children died  You moved house  
        A friend or relative died  You were bleeding and thought you might miscarry 
        One of your children was ill  You started a new job  
        Your partner was ill  You had a test to see if your baby was abnormal 
        A friend or relative was ill  Result on a test that suggested your baby might not be normal 
        You were admitted to hospital You were told that you were going to have twins 
        You were very ill  You heard something that happened might be harmful to the baby 
        Your partner lost his job You took an examination  
        Your partner had problems at work Your house or car was burgled 
        You had problems at work  You had an accident 
Contextual Risks 7 0-3 .53 (.78) You had a major financial problem Housing adequacy  
        You became homeless  Housing Basic Living  
        Your income was reduced  Housing Defects  
        Financial difficulties  
Parental Risks 9 0-5 .51 (84) You were in trouble with the law Psychopathology of mother  
        Your partner was in trouble with the law Substance abuse  
        You were convicted of an offence Crime trouble with police  
        Early parenthood  Crime convictions  
       Maternal education   
Interpersonal Risks 18 0-7 1.19 (1.41) You were divorced  You found that your partner didn't want your child 
    Your partner went away  You argued with your partner 
    You and your partner separated You had arguments with your family or friends 
    Partner Status  Your partner hurt you physically 
    Partner Affection  Your partner hurt your children physically 
        Partner Affection  Your partner hurt your children physically 
        Partner cruelty Your partner was emotionally cruel to you  
      Family Size  Your partner was emotionally cruel to your children  
      Family Major problems  Social Network - Emotional  
        Partner Support  Social Network - Practical  
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OS2. Optimized gene ontology method 
A logistic regression approach was used to test if genes in the test list predicted pathway 
membership while controlling for the number probes annotated to each gene. Pathways were 
downloaded from the Gene Ontology website and all genes annotated to parent terms were 
also included. Illumina UCSC gene annotation was used to create a test gene list from probes 
that were associated with early-onset vs low conduct problems at birth (p< 0.001). All genes 
with at least one methylation probe annotated and annotated to at least one GO pathway were 
considered. Pathways were filtered to those with between 10 and 2000 genes in. After 
applying this method to all pathways, significant pathways (p < 0.05) were taken and grouped 
where overlapping genes explained the signal. This was achieved by taking the most 
significant pathway, and retesting all remaining significant pathways while controlling 
additionally for the best term. If genes in the test list no longer predicted the pathway, the 
term was said to be explained by the most significant pathway, and hence these pathways 
were grouped together. This algorithm was repeated, taking the next most significant 
term, until all pathways had been considered as the most significant or found to be explained 
by a more significant term. GO terms were interpreted exclusively if they if they contained at 
least 2 genes. 
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OS3. Intercorrelations between DNAm levels across the identified sites 
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OS4. Boxplots of mean methylation differences between CP groups across four genome-wide 
significant probes (q<0.05) that are distal to annotated transcripts. 
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OS5. Top 20 enriched biological processes at birth differentiating early-onset vs low CP children based on GO pathway analysis 
 
  GO Pathway N genes 
in study 
Total N genes 
in pathway 
%  P-value Genes  
1 Negative regulation of fat 
cell differentiation 
12 37 32.43% 2.95E-15 WNT3A;GATA2;WWTR1;BBS12;ID4;SOD2;ZFPM2;TCF7L2;NCOR2;FOXO1;JDP2;
ZFPM1 
2 Vesicle transport along 
microtubule 
6 17 35.29% 3.33E-09 PRKCZ;FYCO1;HTT;KIF13A;NDE1;KIF3B 
3 Regulation of cell 
differentiation 
95 1186 8.01% 6.93E-07 ITPKB;PRDM16;WNT3A;ARHGEF2;PRKCZ;TRIM11;RPS6KA1;DISC1;IL6R;TGFB
2;CDC42;ID3;IGFBP5;CTNNA2;ZFP36L2;HDAC4;PAX8;CFLAR;CASP8;ZAP70;N
COA1;CTLA4;FNDC3B;FOXP1;TKT;GATA2;WWTR1;BCL6;ETV5;INPP4B;MSX1;T
LR3;SFRP2;PROM1;PHOX2B;HTT;RAPGEF2;BBS12;GHR;C5orf13;ZSWIM6;OTP;
MEGF10;TFAP2B;NR2E1;TFAP2A;ID4;PRDM1;NOTCH4;SOX4;SOD2;MAPK14;G
LI3;INHBA;HDAC9;LIMK1;ASB4;LRRC17;HGF;ZFPM2;GDF6;PLAG1;TRPS1;MY
ST3;TCF7L2;VAX1;FGFR2;BMPR1A;IL15RA;BDNF;HCCA2;BAD;NCOR2;FGF23;
SSH1;WIF1;PTPN6;STK24;FOXO1;JDP2;RGS6;RCOR1;NKX2-
1;NEDD4;GREM1;ZFPM1;MED24;HOXB8;DCC;PRMT1;PRKACA;HPN;ZBTB46;O
LIG2;RBM9 
4 Negative regulation of 
neural precursor cell 
proliferation 
5 17 29.41% 1.47E-06 GATA2;HTT;NR2E1;VAX1;BDNF 
5 Response to epinephrine 4 10 40.00% 1.48E-06 PDE4B;PDE4D;RNLS;PRKACA 
6 Response to superoxide 4 14 28.57% 1.56E-06 PRDX1;SOD2;ERCC6;MPO 
7 Negative regulation of cell 
differentiation 
48 487 9.86% 1.58E-06 PRDM16;WNT3A;ARHGEF2;TRIM11;ID3;IGFBP5;ZFP36L2;HDAC4;CTLA4;FOXP
1;GATA2;WWTR1;BCL6;INPP4B;MSX1;TLR3;SFRP2;PHOX2B;HTT;RAPGEF2;BB
S12;NR2E1;ID4;NOTCH4;SOX4;SOD2;GLI3;INHBA;LRRC17;ZFPM2;MYST3;TCF7
L2;VAX1;BMPR1A;BDNF;NCOR2;FGF23;FOXO1;JDP2;NKX2-
1;ZFPM1;MED24;HOXB8;DCC;PRMT1;HPN;ZBTB46;OLIG2 
8 Hemopoiesis 41 431 9.51% 1.86E-06 HIPK1;ITPKB;MFAP2;PRG4;WNT3A;PIK3CD;TGFB2;CDC42;CASP9;CD1D;SPTA
1;IFI16;TPO;ZFP36L2;HDAC4;CASP8;ZAP70;TTC7A;MECOM;FOXP1;GATA2;BC
L6;SFRP2;TXK;NOTCH4;SOX4;SOD2;MAPK14;GLI3;INHBA;HDAC9;ZFAT;ASH2
L;TPD52;ANGPT1;MYST3;FGFR2;RCOR1;IREB2;CBFA2T3;ZFPM1 
9 Negative regulation of 
myeloid leukocyte 
differentiation 
8 35 22.86% 3.73E-06 PRDM16;GATA2;INPP4B;TLR3;INHBA;LRRC17;ZFPM1;ZBTB46 
10 Regulation of macrophage 
differentiation 
5 20 25.00% 4.47E-06 CASP8;GATA2;INHBA;PRKACA;ZBTB46 
11 Neutrophil migration 7 37 18.92% 5.48E-06 PDE4B;PIK3CD;TGFB2;FCER1G;PDE4D;PRKACA;ITGB2 
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12 Positive regulation of 
immune system process 
49 626 7.83% 5.89E-06 ITPKB;PDE4B;WNT3A;PRKCZ;PIK3CD;RPS6KA1;IL6R;TGFB2;CDC42;CD1D;MA
PKAPK2;FCER1G;SPTA1;IFI16;WIPF1;CASP8;ZAP70;IGFBP2;CTLA4;FOXP1;BC
L6;NCKIPSD;TLR3;EDNRA;CXCL13;TXK;PDE4D;RPS6KA2;C6orf150;PRDM1;MA
PK14;ELMO1;GLI3;LIMK1;TRIL;IL15RA;IGF2;CD5;BAD;CADM1;BIRC3;IRAK4;P
TPN6;C3AR1;THBS1;PRKCB;GRB2;ELANE;ITGB2 
13 Response to wounding 74 1022 7.24% 6.70E-06 WNT3A;PRKCZ;GNAI3;PIK3CD;CNR2;IL6R;TGFB2;CDC42;ID3;MAPKAPK2;PLA
2G4A;FCER1G;IFI16;HDAC4;RAPGEF4;CFLAR;FN1;IL18RAP;MECOM;GP5;MG
LL;GATA2;ATP2B2;DGKG;BCL6;CXCR6;TLR3;CNO;CXCL13;ARHGAP24;C5orf13
;DST;DSP;SOD2;MAPK14;HIST1H3D;PRKAR1B;GLI3;HDAC9;TRIL;HGF;ZFPM2;
PGCP;ANGPT1;KCNMA1;ALOX5;HPS6;SYT7;IGF2;BDNF;KRAS;CBX5;PTPN6;C3
AR1;RACGAP1;SLC8A3;RCOR1;ITPK1;SLC7A7;THBS1;ZFPM1;PRKCB;GRB2;RP
S6KB1;RAD51C;CCL16;CABLES1;PRKACA;GNA15;ELANE;PLAUR;KIF3B;IL10RB
;ITGB2 
14 Retina layer formation 4 13 30.77% 7.84E-06 HIPK1;PROM1;TFAP2B;TFAP2A 
15 Regulation of gastrulation 6 27 22.22% 1.12E-05 WNT3A;SFRP2;OSR2;BMPR1A;OTX2;MAP2K5 
16 Regulation of ossification 21 172 12.21% 1.17E-05 IL6R;MATN1;TGFB2;ID3;IGFBP5;HDAC4;TKT;SFRP2;TFAP2A;ID4;GLI3;HGF;O
SR2;EGR2;FGFR2;BMPR1A;CREB3L1;FGF23;MGP;GREM1;PRKACA 
17 Forebrain generation of 
neurons 
10 60 16.67% 1.81E-05 WNT3A;RAPGEF2;OTP;NR2E1;TFAP2A;GLI3;LHX6;FGFR2;LHX5;NKX2-1 
18 Immune system process 113 1842 6.13% 3.81E-05 HIPK1;ITPKB;MFAP2;PDE4B;PRG4;WNT3A;ARHGEF2;CD1C;TRIM11;PIK3CD;
RPS6KA1;SNX27;CNR2;IL6R;TGFB2;YTHDF2;CDC42;CASP9;PRDX1;CD1D;MAP
KAPK2;FCER1G;SPTA1;ILF2;IFI16;TPO;ZFP36L2;HDAC4;WIPF1;CASP8;ZAP70;
TTC7A;FN1;IL18RAP;CTLA4;MECOM;FOXP1;GATA2;BCL6;ST6GAL1;NCKIPSD;
UBA7;TLR3;PITX2;SFRP2;CXCL13;TXK;PDE4D;NRG2;RPS6KA2;TAPBP;GNL1;C
6orf150;PSMB8;HLA-
DMB;NOTCH4;SOX4;SOD2;RNF8;MAPK14;ELMO1;PRKAR1B;GLI3;INHBA;HDA
C9;LIMK1;TRIL;LRRC17;ZFAT;EIF2C2;ASH2L;TPD52;ANGPT1;MYST3;PSMB7;F
GFR2;BMPR1A;CD5;BAD;IL18BP;MRE11A;BIRC3;PAN2;FGF23;KRAS;IRAK4;OA
S3;PTPN6;C3AR1;RACGAP1;FLT1;FOXO1;RCOR1;SLC7A7;THBS1;SMAD6;IREB2
;NEDD4;CBFA2T3;ZFPM1;PHLPP2;PRKCB;GRB2;MPO;CCL16;RPL13A;PRKAC
A;ELANE;KIF3B;CST7;IL10RB;ITGB2;POLR3H 
19 Regulation of protein 
export from nucleus 
5 24 20.83% 4.23E-05 XPO1;HTT;SOX4;TCF7L2;PRKACA 
20 Cell differentiation in 
spinal cord 
9 53 16.98% 4.64E-05 WNT3A;LHX4;IFT172;GATA2;SOX4;GLI3;DBX1;LHX5;OLIG2 
 
N.b. GO pathways highlighted in orange are visually depicted in Figure 1D of the article.   
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OS6. Detailed functional characterization of MGLL DNA methylation sites associated with 
early-onset conduct problems 
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Expanded views from the UCSC genome browser of the MGLL gene showing the position of 
the DNAm sites associated with early-onset CP relative to ENCODE regulatory elements. 
The top panel shows functional characterization of the entire MGLL gene. Track numbers are 
displayed on the left-hand site, and represent the following (1) genomic positon of MGLL in 
chromosome 3; (2) genomic coordinates and scale; (3) location of all Illumina 450k probes 
that map onto the MGLL gene (n = 26); (4) location of differentially methylated probes 
associated with early-onset vs low conduct problems (n = 5). These are highlighted in blue to 
facilitate comparison with the regulatory elements displayed in lower tracks (track 6-8). In 
red is the probe that survived genome-wide correction (MGLLcg02503763; all other probes 
significant at p<0.05); (5) schematic representation of the MGLL gene; (6) location of 
transcription factors (based on ChIP-seq data from 91 cell types), where darker shades 
indicate a stronger signal occupancy; (7) DNaseI hypersensitivity clusters (based on ChIP-seq 
data from 125 cell types), where darker shades also indicate a stronger signal; (8) levels of 
enrichment of three histone marks (H3K27Ac, H3K4Me1, and H3K4Me3) across three cell-
types, including blood (GM12878 [red], K562 [purple]) and umbilical vein endothelial 
(HUVEC [blue]) cells; (9) location of common single-nucleotide polymorphisms (SNPs); and 
(10) median levels of MGLL expression across 51 tissues, based on RNA-seq data from the 
NIH Genotype-Tissue Expression (GTEx) project (midpoint milestone data release (V6, 
October 2015). Each bar represents a tissue, and the height of the bar indicates level of 
expression. Of note, yellow bars represent expression levels in brain tissue across multiple 
regions. These tracks are shown again in the lower panel of the figure, but this time 
specifically within the promoter region of MGLL, where our genome-wide significant DNAm 
site (in red) was located. Here, specific transcription factors binding to these regions are also 
shown.
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OS7. Candidate gene follow-up analyses 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene name Chr 
Total N 
probes 
  
Probes significant at p<0.05                                            
(uncorrected) 
  
Gene-level significant                         
(Bonferroni-corrected) 
        N ProbeID   N ProbeID 
Dopaminergic pathway             
    COMT  22 30   3 cg03724721, cg08289189, cg21919834   -- -- 
    DRD2  11 22   3 cg12758687, cg14809166, cg18248586   -- -- 
    DRD4  11 21   1 cg08726248   -- -- 
    MAOA  X 14   2 cg05443523, cg18138788   1 cg05443523 (↑) 
    SLC6A3   5 52   3 cg14502484, cg16703956, cg19440506   -- -- 
Serotonergic pathway             
    HTR1A  5 14   2 cg11615755, cg13666507   -- -- 
    HTR2A  13 25   6 
cg02027079, cg06476131, cg09361691, 
cg14059288, cg16188532, cg20102280 
  -- -- 
    SLC6A4   17 14   2 cg12074493, cg25725890   -- -- 
    TPH1  11 4   1 cg08400935   -- -- 
    TPH2  12 18   2 cg12017635, cg19530293   -- -- 
Neuroendocrine and neurodevelopmental pathway       
    AVP  20 14   1 cg11491381   -- -- 
    BDNF  11 73   8 
cg01225698, cg01418645, cg02527472, 
cg03747251, cg07159484, cg18354203, 
cg20954537, cg25412831 
  2 cg01225698  (↑), cg18354203 (↓) 
    FKBP5  6 32   4 
cg01294490, cg03546163, cg03591753, 
cg07061368 
  1 cg07061368 (↓) 
    NR3C1  5 35   7 
cg03857453, cg08818984, 
cg10847032,cg13648501, cg14558428, 
cg17860381, cg27122725 
  -- -- 
    OXTR  3 17   1 cg19619174   -- -- 
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OS8. Comparison of DNAm levels across the identified loci between early-onset children who persist (i.e. EOP) vs desist (i.e. CL) in conduct 
problems over time 
 
  Early-Onset CP children (n = 174) F p 
  CL trajectory (n = 83)   EOP trajectory (n= 91)     
  Mean Std. Dev. 
  Mean Std. Dev.     
Genome-wide analyses 
  
            
    cg12628061 0.77 0.06   0.77 0.05 0.24 0.62 
    cg02131674 0.77 0.06   0.77 0.05 0.15 0.70 
    cg15384400 0.27 0.07   0.25 0.08 2.00 0.16 
    cg07128473 0.83 0.04   0.84 0.04 0.46 0.50 
    cg02503763 (MGLL) 0.38 0.11   0.38 0.10 0.00 0.99 
    cg21579239 (TTBK2) 0.74 0.07   0.75 0.06 0.13 0.72 
    cg16006965 (GCET2) 0.57 0.06   0.56 0.06 3.11 0.08 
Candidate gene follow-up analyses               
    cg01225698 (BDNF)  0.16 0.04   0.17 0.04 1.32 0.25 
    cg18354203 (BDNF)  0.71 0.07   0.72 0.07 0.74 0.39 
    cg07061368 (FKBP5) 0.81 0.06   0.81 0.04 0.87 0.35 
    cg05443523 (MAOA) 0.37 0.06   0.35 0.05 1.57 0.21 
 
